GSPT1抗体;GSPT1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P13350(GSPT1 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The GSPT1 (G1 to S phase Transition 1) protein, also known as eukaryotic peptide chain release factor GTP-binding subunit ERF3A, plays a critical role in translational termination and cell cycle progression. It functions as a substrate-recruiting component in the ubiquitin-proteasome system, particularly in complexes with E3 ubiquitin ligases, facilitating the degradation of target proteins. GSPT1 has garnered attention in cancer research due to its involvement in oncogenic pathways and resistance mechanisms. For instance, mutations or overexpression of GSPT1 are implicated in hematologic malignancies, such as acute myeloid leukemia (AML), where it interacts with therapeutic targets like CDK9 inhibitors and mediates drug resistance.

GSPT1-targeting antibodies are essential tools for studying its expression, localization, and interaction networks in both normal and diseased states. These antibodies enable applications like Western blotting, immunohistochemistry, and co-immunoprecipitation, aiding in the validation of GSPT1's role in protein degradation and cellular proliferation. Recent therapeutic strategies, including proteolysis-targeting chimeras (PROTACs), exploit GSPT1's degradation function to eliminate oncoproteins, highlighting its potential as a drug target. Antibodies against GSPT1 also support mechanistic studies of small-molecule degraders, providing insights into treatment efficacy and resistance in preclinical models. Overall, GSPT1 antibodies bridge basic research and therapeutic development in oncology.